An American biotechnology company is working on a version of its COVID-19 vaccine that specifically targets the newly identified Omicron variant. Maryland-based Novavax has already started developing the version, with plans to start testing it next month. The updated formulation revolves around a new spike protein, which triggers a response from the human immune system. Scientists will base the spike protein on the genetic sequence of Omicron, a newly identified variant of the CCP (Chinese Communist Party) virus, Novavax told The Epoch Times in an emailed statement. COVID-19 is caused by the CCP virus, sometimes called SARS-CoV-2. The redesigned vaccine will be ready “to begin testing and manufacturing within the next few weeks,” Novavax said on Friday. The company said clinical trial data shows that its vaccine will likely provide protection against new and emerging variants. The vaccine, which utilizes recombinant nanoparticle technology, “allows us to adapt quickly to strain changes and …